ePrints

Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells

Lookup NU author(s): Dr Ian Logan, Hesta McNeill, Susan Cook, Dr Xiaohong Lu, Professor John LunecORCiD, Professor Craig Robson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

BACKGROUND: Small molecule MDM2 antagonists including nutlin-3 have been shown to be effective against a range of cancer cell types and nutlin-3 can inhibit growth of LNCaP xenografts. We compared the efficacy of nutlin-3 in three prostate cancer cell types and provide an insight into the mechanism of nutlin-3. METHODS: Nutlin-3 efficacy was measured using proliferation assays, cell cycle analysis, apoptosis assays, quantitative RT-PCR, and immunoblotting. Chromatin immunoprecipitation (ChIP) assays were also performed. RESULTS: Nutlin-3 can specifically inhibit proliferation of LNCaP cells through cell cycle arrest and apoptosis. This coincides with increased levels of the p53-responsive transcripts p21, PUMA, gadd45, and Mdm2 and recruitment of p53 to chromatin. Nutlin-3 also reduces androgen receptor levels, resulting in altered receptor recruitment to chromatin. CONCLUSION: Our study demonstrates that small molecule MDM2 antagonists might be useful in the treatment of human prostate cancers that retain functional p53 and androgen receptor signaling. © 2007 Wiley-Liss, Inc.

Publication metadata

Author(s): Logan, I., McNeill, H., Cook, S., Lu, X., Lunec, J., Robson, C.N.

Publication type: Article

Publication status: Published

Journal: Prostate

Year: 2007

Volume: 67

Issue: 8

Pages: 900-906

Print publication date: 01/06/2007

ISSN (print): 0270-4137

ISSN (electronic): 1097-0045

URL: http://dx.doi.org/10.1002/pros.20568

DOI: 10.1002/pros.20568

PubMed id: 17440969

Altmetrics

Funding

Share